Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27002104 | 0.88 | SIGMAR1 (0.39) | HTR2ASLC6A4SIGMAR1 | |
| SCHEMBL27002196 | 0.85 | HTR2A (0.37) | HTR2AHTR2CHTR2BSLC6A4SIGMAR1 | |
| SCHEMBL30730987 | 0.81 | HTR2A (0.47) | HTR2AHTR2CHTR2B | |
| SCHEMBL27002187 | 0.79 | HTR2A (0.58) | HTR2AHTR2CHTR2B | |
| SCHEMBL29279553 | 0.79 | SLC6A4 (0.36) | HTR2ASLC6A4SIGMAR1 | |
| SCHEMBL27002101 | 0.78 | HTR2A (0.57) | HTR2AHTR2CHTR2B | |
| SCHEMBL27002153 | 0.76 | HTR2A (0.65) | HTR2AHTR2CHTR2B | |
| SCHEMBL5293465 | 0.75 | MAOA (0.54) | HTR2A | |
| SCHEMBL26056043 | 0.75 | HTR2A (0.59) | HTR2AHTR2CHTR2B | |
| SCHEMBL20970858 | 0.72 | PTGS2 (0.57) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| CN-117642379-A | Phenylalkylamines and methods of making and using the same | 吉尔伽美什制药公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4305019-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | Gilgamesh Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192781-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | PNMT, HTR6, HTR2C | HTR2A 11/4885HTR2C 3/4885HTR2B 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.